BrunoSan Finance Intelligence · April 30, 2026

Finance Intelligence News

Every article includes an Intel Score breakdown — so you know exactly how strong each signal is and where it came from. Not editorial judgment. Signal mathematics.

🏦 RATE DECISION
1.000

ECB and BoE Hold Rates, Cornered by Rising Fuel Prices and Stagflationary Threat

The European Central Bank and Bank of England held key policy rates at 3.00% and 4.25% respectively, signaling that persistent inflation from rising fuel prices is forcing a hawkish pause despite mounting recessionary risks, reflected in the German 10Y-2Y spread inverting to -15 basis points.
⚡ Score 1.000 🌐 1 source 📅 April 30, 2026 Read Analysis →
📊 EARNINGS
1.000

Amazon Q1 Earnings: AWS Re-acceleration to 28% Growth Signals Renewed Enterprise Spend

Amazon reported Q1 2026 EPS of $1.15, beating consensus by 9.5%, driven by a significant re-acceleration in AWS revenue growth to 28% year-over-year, signaling a robust recovery in enterprise cloud demand.
⚡ Score 1.000 🌐 1 source 📅 April 30, 2026 Read Analysis →
📊 EARNINGS
1.000

HSBC and NAB Earnings Outlooks Diverge on Middle East Geopolitical Risk

Upcoming earnings from HSBC and National Australia Bank face direct headwinds from Middle East geopolitical risk, with analysts flagging potential for increased loan-loss provisions, a stark contrast to the more insulated outlook for Singapore's top 3 banks.
⚡ Score 1.000 🌐 1 source 📅 April 30, 2026 Read Analysis →
🏦 RATE DECISION
1.000

Fed Holds Rates at 5.50%, Hawkish Pause Creates Headwind for Gold Buyers

The Federal Reserve held the federal funds rate at 5.25%-5.50% on April 29, 2026, signaling persistent inflation risks that challenge the case for gold's continued rally despite recent dip-buying activity.
⚡ Score 1.000 🌐 1 source 📅 April 30, 2026 Read Analysis →
🚀 IPO
1.000

Novo-Backed Avalyn Pharma Prices Upsized IPO at $19, Raising $300M for Lung Disease Pipeline

Avalyn Pharma (AVLY) raised $300 million in an upsized IPO, pricing 15.8 million shares at $19, the top of its range, signaling robust institutional demand for specialized biopharma assets backed by strategic capital like Novo Holdings and establishing a new valuation benchmark for the sector.
⚡ Score 1.000 🌐 1 source 📅 April 30, 2026 Read Analysis →